| 0 (0%) | 04-25 17:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.04  |
1-year : | 21.68 |
| Resists | First : | 17.16 |
Second : | 18.56 |
| Pivot price | 16.05 |
|||
| Supports | First : | 14.89 |
Second : | 12.38 |
| MAs | MA(5) : | 15.38 | MA(20) : | 16.49 |
| MA(100) : | 17.57 |
MA(250) : | 18.08 |
|
| MACD | MACD : | -0.6  |
Signal : | -0.5 |
| %K %D | K(14,3) : | 10.9 |
D(3) : | 10.5 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 24.51 | Low : | 14.18 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SRI ] has closed above bottom band by 29.8%. Bollinger Bands are 46.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 15.38 - 15.46 | 15.46 - 15.52 |
| Low: | 14.71 - 14.8 | 14.8 - 14.87 |
| Close: | 15.22 - 15.35 | 15.35 - 15.47 |
Wed, 24 Apr 2024
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 ... - GlobeNewswire
Mon, 22 Apr 2024
Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major ... - Nature.com
Fri, 22 Mar 2024
Concomitant SSRI and Oral Anticoagulant Use Tied to Major Bleeding Risk - Medpage Today
Sun, 03 Mar 2024
‘It feels like we’ve been lobotomised’: the possible sexual consequences of SSRIs - The Guardian
Tue, 20 Feb 2024
What We Know About Antidepressants and Pregnancy - Healthline
Thu, 01 Feb 2024
2 common types of antidepressants were safe for most stroke survivors - American Heart Association
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 28 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 101.8 (%) |
| Shares Short | 705 (K) |
| Shares Short P.Month | 586 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.43 |
| Profit Margin | -0.6 % |
| Operating Margin | 2.6 % |
| Return on Assets (ttm) | 1.6 % |
| Return on Equity (ttm) | -1.9 % |
| Qtrly Rev. Growth | -0.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 35.26 |
| EBITDA (p.s.) | 1.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 5 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -80.79 |
| PEG Ratio | 182.7 |
| Price to Book value | 1.47 |
| Price to Sales | 0.43 |
| Price to Cash Flow | 85.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|